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Background: Resveratrol is a natural compound that affects energy metabolism and is also known to possess an
array of cardioprotective effects. However, its overall effects on energy metabolism and the underlying mechanism
involved in cardioprotection require further investigation. Herein we hypothesize that ATP-sensitive potassium
(K-ATP) channels as molecular sensors of cellular metabolism may mediate the cardioprotective effects of resveratrol.
Methods: Kir6.2 knockout, Kir6.1 heterozygous and wild-type (WT) mice were subjected to ischemia/reperfusion injury
and were injected with resveratrol (10 mg/kg, i.p). Myocardial infarct size, serum lactate dehydrogenase (LDH) and
creatine kinase (CK) activities were determined. Neonatal cardiomyocytes were used in in vitro assays to investigate the
underlying mechanism of resveratrol in cardioprotection.
Results: Resveratrol treatment significantly reduced myocardial infarct size and serum LDH and CK activity and inhibited
oxygen-glucose deprivation/reoxygenation – induced cardiomyocyte apoptosis in WT and Kir6.1 heterozygous mice,
but Kir6.2 deficiency can abolish the cardioprotective effects of resveratrol in vivo and in vitro. We further found that
resveratrol enhanced 5′-AMP-activated protein kinase (AMPK) phosphorylation and promoted the association of AMPK
with Kir6.2. Suppression of AMPK attenuated and activation of AMPK mimicked the cardioprotective effects of resveratrol
in cardiomyocytes. Notably, Kir6.2 knockout also reversed the cardioprotection of AMPK activator.
Conclusions: Our study demonstrates that resveratrol exerts cardioprotective effects through AMPK -Kir6.2/K-ATP signal
pathway and Kir6.2-containing K-ATP channel is required for cardioprotection of resveratrol.
Keywords: Resveratrol, ATP-sensitive potassium channel, Kir6.2, Myocardial Ischemia/reperfusion, 5′-AMP-activated
protein kinaseBackground
Resveratrol (3, 4′, 5-trihydroxy-trans-stilbene) is a natur-
ally existing polyphenol phytoalexin originally isolated
from the roots of white hellebore and later found in a var-
iety of fruits, vegetables, and grape skins [1]. Resveratrol
has extensive biological and pharmacological effects, such
as anti-atherosclerosis [2], anti-inflammation [3], anti-
oxidation [4], and anti-cancer activities [5]. Recent studies
have demonstrated that resveratrol can protect the heart
from ischemia/reperfusion (I/R) injury [6]. Suppression of
superoxide levels, activation of potassium channels and
translocation of GSK-3β have been proposed to mediate
the cardioprotective effects of resveratrol [6,7]. However,* Correspondence: ghu@njmu.edu.cn
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stated.the underlying mechanisms of resveratrol against myocar-
dial I/R injury have not yet been fully explored.
ATP sensitive potassium (K-ATP) channels are hetero-
octamers composed of pore-forming Kir6.x (6.1 or 6.2)
subunits and sulfonylurea receptor (SUR1 or SUR2) regu-
latory subunits, regulated by intracellular ATP and ADP
concentrations [8] K-ATP channels are highly expressed
in cardiomyocytes and play crucial roles in ischemic pre-
conditioning (IPC) [9,10]. Potassium channel openers
mimicked the cardioprotection and the K-ATP channel
blocker abolished the effect of IPC [11,12]. In addition,
Kir6.2 knockout abolished Ischemia- and diazoxide- in-
duced preconditioning [10,13]. These results indicate that
K-ATP channel is a key target for cardioprotection. Im-
portantly, resveratrol exerts multiple cardioprotective ef-
fects similar to those associated with energy metabolism,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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brane potential. However, the link between resveratrol and
K-ATP channel in myocardial I/R injury remains unclear.
Therefore, it is intriguing to determine whether K-ATP
channel is involved in the cardioprotection of resveratrol.
In the present study, Kir6.2 knockout mice (Kir6.2-/-)
and Kir6.1 heterozygote mice (Kir6.1+/-) were used to
define the roles of Kir6.1- and Kir6.2- containing K-
ATP (Kir6.1/K-ATP and Kir6.2/K-ATP) channels in
resveratrol-mediated protection against myocardial I/R
injury. Our results demonstrate that Kir6.2/K-ATP chan-
nels are required for resveratrol-mediated protection
against myocardial I/R injury.
Methods
Animals and reagents
Kir6.2 knockout mice donated by Professor Miki (Kobe
University, Japan), Kir6.1 heterozygous mice (purchased
from MMRRC Company) and wild-type (WT) mice
were bred and maintained in the Animal Resource
Centre of the Faculty of Medicine, Nanjing Medical
University. Knockout of the Kir6.2 gene was confirmed
by RT-PCR. Littermate mice were used as WT controls,
as previously described [14]. Age-matched adult male
mice (3 months old) were utilized for the experiments.
All experimental procedures were conducted in strict ac-
cordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals and all ani-
mals were treated according to protocols approved by
IACUC (Institutional Animal Care and Use Committee
of Nanjing Medical University).
Resveratrol was purchased from Cayman Chemical
Company (Ann Arbor, MI), and dissolved in either etha-
nol or DMSO. Evans blue, triphenyl tetrazolium chloride
(TTC), compound C and 5-aminoimidazole-4-carboxa-
mide- ribonucleoside (AICAR) were purchased from
Sigma Chemical Company.
Myocardial ischemia-reperfusion (I/R) protocol
Mice were anesthetized with 2% isoflurane. The skin on
the neck was opened and the trachea was cut down to
guide the placement of an end tracheal tube. The animals
were mechanically ventilated with room air supple-
mented with oxygen using an end tracheal tube and a ro-
dent ventilator. During the operation, body temperature
was maintained at 37°C using a heat lamp. After a left
thoracotomy was performed in the fourth intercostal
space, the pericardium was opened to expose the heart.
A 6-0 silk suture slipknot was passed around the prox-
imal portion of the left anterior descending artery (LAD)
at a point two thirds of the way between its origin near
the pulmonary conus and the cardiac apex. Regional is-
chemia was confirmed by visual inspection of the discol-
oration of the heart. Mice were subjected to 30 min ofligation, followed by reperfusion by releasing the slipknot.
Successful reperfusion was confirmed by visualization of
the return of a bright red color in the previously disco-
lored region. Sham-operated mice (Sham) underwent the
same surgical procedure but without the ligation of the
LAD. It has been demonstrated that the cardioprotective
effect of resveratrol was detectable at 5 mg/kg in isolated
rat hearts [15,16]. According to the dose of resveratrol
used in rats, we performed all experiments with 10 mg/kg
resveratrol in our study, because the resveratrol 10 mg/kg
is the most effective dose that can protect against myo-
cardial ischemia/reperfusion injury in mice, whereas at a
lower dose of 1 mg/kg resveratrol or at higher dose of
100 mg/kg resveratrol was found to be only partially pro-
tective. In the experiment, resveratrol (10 mg/kg) or 15%
ethanol vehicle (10 ml/kg) was intraperitoneally injected
into the mice at min 60 before the ligation.
Determination of myocardial infarct size
At the end of 24-hour reperfusion, mice were re-
anesthetized, and LAD was re-occluded in the same lo-
cation as before. Evans blue (1 ml of the 2% solution)
was injected into the left ventricular cavity to perfuse
the non-ischemic area, delineating the myocardium as
dark blue. The area at risk (AAR), the portion of the left
ventricle supplied by the previously occluded coronary
artery, was determined by the absence of blue. The heart
was then excised, rinsed of excess blue dye, trimmed of
atrial tissue, and sliced into 1-mm-thick cross sections.
After being incubated in 1% TTC at 37°C for 25 min to
stain the viable myocardium red, the slices were then
fixed with 10% formaldehyde. The sizes of the infarct
area and risk area were determined by individuals
blinded to the experimental groups using computer-
assisted planimetry (NIH software Image 1.0). Infarct
size was calculated as a percentage of AAR to indirectly
assess the degree of myocardial damage.
Cultures of neonatal cardiomyocytes
Ventricular myocytes were prepared from embryonic
mice (E19-20) by trypsin digestion. Briefly, ventricles of
mice were aseptically removed immediately after decapi-
tation. Isolated hearts were pooled, minced, and digested
at 37°C with trypsin. Dissociated cells were plated for 60
minutes onto 100-mm-diameter dishes to reduce the
number of nonmyocardial cells, in the presence of
Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO)
supplemented with 10% fetal serum (Hyclone Labora-
tories, Logan, UT). After being centrifuged at a low
speed, cells were plated at a low density (4 × 105 cells
mL-1) in 24-well plates, and incubated for 24 h at 37°C
in a humidified atmosphere of 95%O2/5%CO2. The cul-
ture medium was then changed to DMEM containing
10% fetal serum and 0.1 mM 5-BrdU.
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experimental protocol
Cardiomyocytes were prepared as described above, and
used on day 4 of culture. Resveratrol (compound C or
AICAR) was added to the medium for 30 min before
OGD and maintained in the medium during the subse-
quent twenty-four hours of recovery period. For OGD,
the culture medium was replaced by thorough exchange
with glucose-free medium containing 25 mM sucrose,
and then the cells were incubated in a humidified atmos-
phere of 5% CO2, 94 N2% and 1% O2. Twenty four hours
after reoxygenation, cells were fixed with 4% formalde-
hyde in PBS for immunocytochemistry.
Hoechst staining
Twenty four hours after OGD, cardiomyocyte monolayer
was fixed and stained with Hoechst 33342 (Sigma) to
quantify apoptotic cells. The morphological features
of apoptosis (cell shrinkage, chromatin condensation,
and fragmentation) were monitored by Nikon Optical
TE2000-S inverted fluorescence microscope. At least 400
cells from 12 randomly selected fields per well were eval-
uated to determine the number and percentage of cells
exhibiting apoptosis, and each treatment was performed
in duplicate.
Levels of CK and LDH in serum and culture medium
Creatine kinase (CK) and lactate dehydrogenase (LDH)
in serum and culture media were determined using a
commercially available kit (Nanjing Jiancheng Bioengin-
eering Institute, Nanjing, China).
Coimmunoprecipitation
The lysates from cardiomyocytes were immunoprecipi-
tated with anti-AMPK antibody followed by protein A/G
plus agarose (Santa Cruz Biotechnology). After washing,
bound proteins were eluted from the beads and analyzed
by immunoblot for Kir6.2.
Western blot analysis
The left ventricle was homogenized in lyses buffer
(Beyotime, China) and protein concentration was deter-
mined by the Bradford assay (Bio-Rad, Hercules, CA,
USA). Proteins were separated on 10% Tris-HCl polyacryl-
amide gels (Bio-Rad) and transferred to a PVDF mem-
brane. After blocking, the blots were incubated with
anti-phospho-AMPK (2531, Cell Signaling Technology,
Beverly, MA, USA), anti-AMPK (2532, Cell Signaling
Technology, Beverly, MA, USA), anti-Kir6.2 (sc-20809,
Santa Cruz Biotechnology) and anti-Kir6.1 (sc-11224,
Santa Cruz Biotechnology) in TBST overnight at 4°C, and
then with horseradish peroxidase (HRP) conjugated sec-
ondary antibodies. Immunoreactive bands were detected
by enhanced chemiluminescence (ECL) plus detectionreagent (Pierce, Rockford, IL, USA), and analyzed using
an Omega 16ic Chemiluminescence Imaging System
(Ultra-Lum, CA, USA).
Statistical analysis
Data are presented as mean ± SEM. The significance of
the difference with different treatments and genotypes
was determined by one-way or two-way ANOVA,
followed by the Tukey’s post hoc test. Differences were
considered significant at P < 0.05.
Results
Resveratrol increases the expression of Kir6.2 subunits in
heart following I/R injury
To investigate the roles of K-ATP channels in the cardio-
protective effects of resveratrol, we first examined the ex-
pression of Kir6.1 and Kir6.2 subunits in the left ventricle
of WT mice after I/R injury with or without resveratrol
treatment. Western blotting showed that protein expres-
sion of Kir6.1 and Kir6.2 were not changed after I/R in-
jury. Resveratrol (10 mg/kg) induced a significant increase
of Kir6.2 subunits expression in the left ventricle of WT
mice after I/R injury (2.22 ± 0.18 vs. 1.14 ± 0.15, P < 0.05,
Figure 1A). However, the expression levels of Kir6.1 sub-
units were not affected by resveratrol treatment (1.12 ±
0.15 vs. 0.94 ± 0.14, P > 0.05, Figure 1B). These results sug-
gest that Kir6.2/K-ATP channels may be involved in the
cardioprotection of resveratrol.
Kir6.2 knockout abolishes the protection of resveratrol
against I/R injury in mice
To further determine the roles of K-ATP channels in
resveratrol mediated protection against myocardial I/R
injury, we compared myocardial infarct size in WT,
Kir6.2 knockout (Kir6.2-/-) and Kir6.1 heterozygote mice
(Kir6.1+/-). Figure 2A showed representative photograms
of myocardial slices stained with Evans blue dye to AAR
and TTC to delineate infarct areas. There were no sig-
nificant differences in the size of the AAR among three
genotypic mice with or without resveratrol treatment
(Figure 2B). The infarct sizes were similar between WT
mice and Kir6.2-/- mice subjected to I/R injury (37% ±
3% vs 40% ± 3%). Kir6.1+/- mice exhibited the greater in-
farct size than WT mice after I/R injury (48% ± 4% vs
37% ± 3%, Figure 2C). Resveratrol significantly decreased
the infarct size from 37% ± 3% to 21% ± 1% in WT mice
and from 48% ± 4% to 33% ± 2% in Kir6.1+/- mice, re-
spectively. However, resveratrol failed to reduce the in-
farct size in Kir6.2-/- mice (45% ± 2%, Figure 2C).
In addition, serum LDH and CK activities, markers for
the confirmation of myocardial injury, were determined
after I/R injury. Serum CK and LDH activities were sig-
nificantly increased in WT mice, Kir6.2-/- mice and
Kir6.1+/- mice subjected to I/R injury. Treatment with
Figure 1 Resveratrol increased the expression of Kir6.2 subunits in heart following ischemia/reperfusion injury. (A-B) Representative
immunoblots and quantification of myocardial protein extracts for analysis of Kir6.2 (A) or Kir6.1 protein (B) (n = 5/group). Data are represented as
means ± SEM. *P < 0.05. I/R = ischemia/reperfusion; Res = resveratrol.
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and LDH elevation in WT and Kir6.1+/- mice (Figure
2D-E). Similarly, resveratrol did not substantially reduce
serum CK and LDH elevation in Kir6.2-/- mice after I/R
injury (Figure 2D-E). These results indicate that protection
of resveratrol against I/R injury is dependent on Kir6.2/K-
ATP channels, rather than Kir6.1/K-ATP channels.
Kir6.2 deficiency reverses protection of resveratrol
against OGD/R injury in cardiomyocytes
Cardiomyocytes identified by α-myosin heavyweight
chain (α-MHC) monoclonal antibody (Figure 3A) were
cultured to analyze the protective effects of resveratrol
in vitro. Cardiomyocytes were exposed to 3 h of OGD
plus 24 h of reoxygenation in the presence or absence
of resveratrol, and cell apoptosis was assessed with
Hoechst33342 and cell injury was reflected by LDH re-
lease. OGD/R remarkably increased the number of
apoptotic cells and LDH leakage in each genotype. How-
ever, no significant difference was observed in the num-
ber of apoptotic cells among WT, Kir6.2-/- and Kir6.1+/-
groups. Resveratrol (10 μM) markedly inhibited OGD/R-
induced cell apoptosis and LDH leakage in WT and
Kir6.1+/- groups (Figure 3B-D). But, resveratrol failed to
reduce the number of apoptotic cells and LDH release in
Kir6.2-/- group (Figure 3B-D). These results demonstrate
that Kir6.2/K-ATP channels are required for the cardio-
protection of resveratrol in cardiomyocytes.
AMPK - Kir6.2/K-ATP channel signal pathway mediates
cardioprotection of resveratrol
Activation of AMPK in the heart protects cardiac ischemic
injury [17]. Resveratrol treatment significantly enhanced
AMPK phosphorylation in the ischemic heart followingreperfusion (Figure 4A), suggesting that AMPK may be in-
volved in cardioprotective effects of resveratrol. To further
identify the roles of AMPK in cardioprotection of resvera-
trol, cardiomyocytes were treated with AMPK inhibitor
compound C and AMPK activator AICAR. Suppression of
AMPK markedly attenuated the protective effects of res-
veratrol against OGD/R injury in WT cardiomyocytes as
determined by cell apoptosis and LDH leakage (Figure 4B-
D). In contrast, activation of AMPK mimicked the cardio-
protective effects of resveratrol as confirmed by decreased
OGD/R-induced cell apoptosis and LDH leakage in WT
cardiomyocytes (Figure 4E-G). Most notably, Kir6.2
knockout reversed cardioprotective effects of AMPK acti-
vation (Figure 4E-G), suggesting AMPK might be an up-
stream of Kir6.2/K-ATP channels. Together, these results
indicate that resveratrol promotes the survival of cardiac-
myocytes via activation of AMPK - Kir6.2/K-ATP channel
signal pathway.
Resveratrol enhances the association of AMPK with Kir6.2
in cardiomyocytes
It has been reported that AMPK mediates precondition-
ing in cardiomyocytes by regulating the activity and re-
cruitment of sarcolemmal K-ATP channels [18]. To
investigate the possible mechanism of AMPK regulating
Kir6.2/K-ATP channel in resveratrol – mediated the car-
dioprotection, the co-immunoprecipitation experiment
was performed using an anti-AMPK antibody in cardio-
myocytes. As shown in Figure 5 A-B, AMPK was found
to interact with Kir6.2, and resveratrol treatment led to
a significant increase in Kir6.2-AMPK association. These
results suggest that resveratrol protects against car-
diacmyocyte apoptosis by enhancing the association of
Kir6.2 with AMPK.
Figure 2 Kir6.2 knockout abolished the protection of resveratrol against ischemia/reperfusion injury in mice. (A) Representative
photograms of myocardial slices stained by Evans-blue/TTC. (B) Myocardial area at risk expressed as percentage of total area. (C) Myocardial
infarct size expressed as percentage of AAR (n = 8/group). *P < 0.01 vs. corresponding I/R group; #P < 0.05 vs. WT I/R group. (D-E) Cardiac injury
determined by serum CK (D) and LDH activity (E) (n = 8/group). Data are represented as means ± SEM. *P < 0.01 vs. corresponding sham group;
#P < 0.01 vs. corresponding I/R group.
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In the present study we demonstrated that Kir6.2 knock-
out abolished the protection of resveratrol against myo-
cardial ischemia/reperfusion injury in vivo and in vitro.
Resveratrol enhanced the activity of AMPK and pro-
moted the association of AMPK with Kir6.2. Suppres-
sion of AMPK attenuated the cardioprotection of
resveratrol whereas activation of AMPK mimicked pro-
tective effects of resveratrol. In addition, Kir6.2 knockout
reversed the cardioprotective effects of AMPK activa-
tion. Thus, Kir6.2/K-ATP channel is required for
resveratrol-mediated protection against myocardial is-
chemia/reperfusion injury and AMPK-Kir6.2/K-ATPchannel signal pathway mediates cardioprotection of res-
veratrol (Figure 5C).
K-ATP channel is a kind of molecular sensors that
plays a critical role in cardiovascular adaptive response
under the challenge of stress [19]. The cardiac K-ATP
channels are composed of Kir6.2 subunits in combin-
ation with SUR2A [20], while Kir6.1 subunit is a major
molecular component of vascular smooth muscle K-ATP
channels [21]. Opening K-ATP channels blocks cardio-
myocyte apoptosis in ischemia-reperfusion [22]. How-
ever, the specific roles of Kir6.1 and Kir6.2 in myocardial
protection remain unclear. As Kir6.1 knockout mice
could not endure I/R injury (the mortality rate within 24
Figure 3 Kir6.2 knockout abolished the protection of resveratrol against OGD/R injury in cardiomyocytes. (A) Representative
photomicrographs of cardiomyocytes stained with anti-α-myosin heavyweight chain monoclonal antibody. (B-D) The cardiomyocytes were
pretreatment with resveratrol for 30 min following subjected to 30 min OGD plus 24 hours of reoxygenation. OGD/R induced cell injuries
were assessed by staining with Hoechst 33342 (B, D) and measuring LDH release (C) (n = 6). Data are represented as means ± SEM from six
independent experiments. *P < 0.01 vs. corresponding control group; #P < 0.01 vs. corresponding OGD/R group. Arrows point to apoptotic nuclei,
Scale bar: 100 μm.
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Kir6.2 knockout mice were used to subject to I/R injury
in the present study. We found that the infarct size was
much larger in Kir6.1+/- mice compared to WT mice fol-
lowing myocardial I/R injury. But, no significant differ-
ence was detected in isolated cardiomyocyte apoptosis
after OGD/R treatment between WT and Kir6.1+/- mice.
Kir6.1/K-ATP channel has been demonstrated to be crit-
ical in the regulation of vascular tone, especially in the
coronary arteries [23] . As a result, more severe damage
in Kir6.1+/- mice induced by I/R injury might be due to
vasodilatation disorder, instead of cardiomyocyte dys-
function. Furthermore, there were no significant differ-
ences in infarct size between the WT and Kir6.2-/- mice
after I/R injury, which was consistent with the report of
Masashi Suzuki [24].
Recent studies suggest that resveratrol enhances activ-
ity of the K-ATP channels in rat hearts [25] and activa-
tion of the K-ATP channel is necessary for resveratrol
action [26]. As opposed, the experiments on the mouse
beta cell line revealed that resveratrol blocked K-
ATP channels [27] by directly binding to sulfonylureareceptor 1 (SUR1) of K-ATP channel [28]. This discrep-
ancy in the results obtained on the various experimental
models strongly suggests tissue and species specificity of
resveratrol. In addition, pancreatic β-cell K-ATP chan-
nels are thought to be composed of Kir6.2 and SUR1
subunits [29], and it is plausible that SUR1 may not be
primarily expressed in ventricular myocytes [30]. Resver-
atrol is specific to SUR1 subunits, and thus it causes
opening of Kir6.2 SUR2A K-ATP channel in cardiac tis-
sues but blocks Kir6.2 SUR1 K-ATP channel in pancre-
atic tissues. It is not immediately clear how to reconcile
these different outcomes, and further work may be
needed to determine whether there is a differential
mechanism involved.
Emerging evidence indicates that resveratrol protects
cardiomyocytes from I/R injury via a combination of
suppression of superoxide levels and activation of potas-
sium channels [7]. However, the relation of K-ATP chan-
nel and resveratrol in I/R injury remains unknown.
Thus, the aim of this study was designed to assess the
roles of Kir6.2 or Kir6.1–containing K-ATP channel in
cardioprotection of resveratrol under I/R injury. Our
Figure 4 AMPK-Kir6.2/K-ATP channel mediated cardioprotection of resveratrol. (A) Representative immunoblots and quantification of
myocardial protein extracts for analysis of total AMPK and p-AMPK obtained from wild type (WT) hearts (n = 6/group). *P < 0.05 vs. WT sham group,
#P < 0.05 vs. WT I/R group. (B-D) After preincubation with Compound C (CC, 10 μM) for 30 min followed by resveratrol (Res, 10 μM) 30 min,
cardiomyocytes were subjected to OGD device. Cell injuries were assessed by staining with Hoechst 33342 (B-C) and measuring LDH release (D). Scale
bar: 100 μm. Arrows point to apoptotic nuclei. Data are represented as means ± SEM from six independent experiments. *P < 0.05 vs. corresponding
OGD/R group; #P < 0.05 vs. corresponding OGD/R + Res group. (E-G) WT and Kir6.2-/- (KO) myocytes were treatment with AICAR (50 μM) following
subjected to OGD/R device. Cell injuries were assessed by staining with Hoechst 33342 (E-F) and measuring LDH release (G). Data are represented as
means ± SEM from six independent experiments *P < 0.01 vs. corresponding control group; #P < 0.01 vs. corresponding OGD/R group.
Figure 5 Resveratrol enhanced the association of AMPK with Kir6.2 in cardiomyocytes. A-B, The interaction of Kir6.2 and AMPK was
analyzed by immunoprecipitation and western blot analysis in cardiomyocytes in the presence of resveratrol. Data are represented as means ±
SEM from four independent experiments *P < 0.05. C, Schematic layouts of showing Kir6.2/K-ATP channels are required for the protection of
resveratrol against ischemia/reperfusion injury.
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decreased the activity of serum LDH and CK following
I/R injury, and Kir6.2 knockout abolished the cardiopro-
tective effects of resveratrol in vivo. In addition, Kir6.2
knockout also reversed the suppressive effects of resver-
atrol on cardiomyocyte apoptosis after OGD/R treat-
ment in vitro. But, Kir6.1 knockdown failed to abolish
the cardioprotection of resveratrol. These findings in-
dicate that Kir6.2/K-ATP channel is required for
resveratrol-mediated cardioprotection.
It is well known that the most prominent role of K-
ATP channels in cardiovascular system is that opening
of this channel can protect cardiac myocytes against is-
chemic injuries. K-ATP channels are present in multiple
tissues and cell types within the cardiovascular system
and these channels differ from each other in terms of
their biophysical and pharmacological properties. The
properties of K-ATP channels are different in various tis-
sues due to the combinations of the subunits forming
the channel. The “cardiac” K-ATP channel has con-
ventionally been thought to consist of Kir6.2/SUR2A
subunits. Although SUR1 subunits are not essential
subunits of ventricular sarcolemmal K-ATP channels,
the evidence is strong that SUR1 subunits are also
expressed in the heart (particularly in atria) and that
they may have a functional role. In contrast to Kir6.2-
null and SUR2-null mice, SUR1-null mice are protected
from ischemia/reperfusion [31]. One interpretation is
that SUR1 subunits might actually contribute to ische-
mic or post-ischemic damage. SUR1 levels are up-
regulated after ischemic events; even in tissues where it
is not normally expressed, such as the endothelium [32].
Recent data suggest that SUR1 subunits associate with
TRPM4 subunits [33], which may modulate the mem-
brane potential and ionic gradients, thus contributing to
post-ischemic injury. It was recently demonstrated that
resveratrol is a natural SUR1 ligand that can induce
apoptosis in a SUR1 isoform-specific manner [28]. One
might predict that resveratrol reduces infarct size after
ischemia/reperfusion by blocking the cardiovascular
SUR1-containing channels.
Resveratrol provides cardioprotection by triggering dif-
ferent endogenous signaling pathways including oxidative
stress/antioxidant defense system, glucose/insulin metab-
olism, iNOS/nitrotyrosine, and preconditioning, which
are associated with energy metabolism [34-36]. AMPK is
an energy sensor protein that is activated in response to
ATP depletion [37]. AMPK activation plays a critical
roles in ischemia/reperfusion injury in the heart [38,39].
A recent report demonstrated that resveratrol protected
ROS-induced cell death by activating AMPK in the H9c2
cardiac muscle cell line [40]. In the present study, resver-
atrol enhanced AMPK activation in ischemic heart.
Blockade of AMPK activity abolished the suppressiveeffects of resveratrol on cardiomyocyte apoptosis. More-
over, activation of AMPK mimicked protective effect of
resveratrol on survival of cardiomyocytes. Taken together,
these data indicate that resveratrol can exert beneficial
actions on the cardiovascular systems partly through
the AMPK-dependent mechanism. Furthermore, recent
study has showed that AMPK mediates preconditioning
in cardiomyocytes by regulating the activity and recruit-
ment of sarcolemmal K-ATP channels, but the exact
mechanism is still unclear [18]. In our study, we found
that AMPK interacted with Kir6.2 and resveratrol in-
creased the association of Kir6.2 with AMPK. This inter-
action may trigger and promote Kir6.2/K-ATP channel
opening, which mediates cardioprotection of resveratrol.
Notably, Kir6.2 knockout abolished the cardioprotection
of AMPK activation, indicating that Kir6.2/K-ATP chan-
nel might be downstream of AMPK. Thus, resveratrol
enhances the AMPK phosphorylation, which in turn in-
creases the association of AMPK with Kir6.2, and then
promotes Kir6.2/K-ATP channel opening, subsequently
protects against I/R injury.
Conclusions
Resveratrol exerts cardioprotective effects through
AMPK -Kir6.2/K-ATP signal pathway and Kir6.2-con-
taining K-ATP channel is required for cardioprotection
of resveratrol. Modulation of the energy metabolic path-
way via AMPK or Kir6.2/K-ATP could be a novel cardi-
oprotective strategy for I/R injury.
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